DSIP Spray10mg
DSIP Spray Canada — Nasal Spray
Delta Sleep–Inducing Peptide — Nasal Spray
DSIP, also known as Delta Sleep–Inducing Peptide, is a synthetic neuropeptide developed for controlled laboratory research. It was originally identified during investigations into sleep-phase regulation and neuroendocrine signaling systems.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
DSIP, also known as Delta Sleep–Inducing Peptide, is a synthetic neuropeptide developed for controlled laboratory research. It was originally identified during investigations into sleep-phase regulation and neuroendocrine signaling systems.
In scientific literature, DSIP is studied within experimental models examining circadian-associated pathways, central nervous system signaling frameworks, and stress-related regulatory mechanisms under in vitro and preclinical research conditions.
Third-party tested for purity, ID, quantity.
DSIP is a short neuropeptide first reported in the 1970s during investigations into delta-wave activity and sleep-associated physiological processes. Following its identification, research expanded into broader neuroendocrine and central nervous system signaling models.
Experimental studies examine DSIP within controlled laboratory frameworks to better understand its interaction with circadian-associated mechanisms and hypothalamic-pituitary regulatory pathways.
Delta Sleep–Inducing Peptide was initially isolated during studies focused on sleep physiology and delta-wave modulation. Early investigations centered on its role within central nervous system research models, with later work examining neuroendocrine signaling interactions under controlled conditions.
Over time, DSIP became a recurring subject in laboratory research exploring peptide-based signaling within neurological and regulatory pathway systems.
Laboratory investigations into DSIP have explored its interaction with neuroendocrine signaling systems and circadian-related regulatory pathways. Research models evaluate peptide behavior within central nervous system frameworks and stress-response signaling under controlled in vitro and preclinical conditions.
1 of the 4 areas below are addressed directly by a paper cited on this page.
No paper cited on this page reports on neuroendocrine. This heading marks where DSIP Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Monnier 1977, Schoenenberger 1978, Schneider-Helmert 1981. The work appeared in Pflugers Arch and Int J Clin Pharmacol Ther Toxicol. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on central or nervous. This heading marks where DSIP Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on stress or response. This heading marks where DSIP Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 10 primary papers published between 1977 and 2006 — a reasonably developed body of work for a research compound. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for DSIP Spray, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
DSIP Spray is also referred to as delta sleep peptide, the sleep peptide.
DSIP Spray is commonly described online in connection with sharper focus, better memory and improved mood. In the research literature the same compound is filed under neuroendocrine signaling pathway models, circadian and delta-wave research frameworks and central nervous system regulatory studies.
The 10 papers cited on this page, published between 1977 and 2006 (1 review) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for DSIP Spray is per lot, not per product. The current 10mg lot DSIP-CA-26F-10 returned 99.623% purity, 11.85 mg measured, 118.5% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
The lot code printed on the vial matches the code on the certificate for DSIP Spray. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy DSIP Spray in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
DSIP Spray ships as a prepared solution rather than as lyophilized powder, so it is already past the point at which a powder would be reconstituted. That shortens handling but tightens storage: a compound in solution is less stable than the same compound dry, and refrigeration from arrival onward is the relevant control.
The stability window for a solution is shorter than the shelf life of a sealed lyophilized vial of the same compound. Records for laboratory work in this format should note the date the unit was opened, not only the date it was received.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 12mg of lyophilized DSIP. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the lyophilized peptide. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide.
PubMedThe delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflugers Arch 376(2):119–129.
PubMedAcute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol 19(8):341–345.
PubMedThe influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.
PubMedCharacterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP).
PubMedEffects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol 27(2):120–129.
PubMedRelated
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
